Intensity Therapeutics reports complete pathological response in 5 of 7 patients receiving INT230-6 plus standard care in breast cancer trial

Bitget2026/10/23 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Intensity Therapeutics will present initial INVINCIBLE-4 breast cancer trial results at the ESMO meeting on Oct. 23, 2026.
Most of seven patients receiving INT230-6 with standard therapy had no invasive cancer remaining in breast tissue or affected lymph nodes.
All seven patients qualified for breast-conserving surgery.
Dose-limiting local skin reactions prompted a protocol change to one injection at a lower drug volume relative to tumor size.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230800PR_NEWS_USPR_____NE78424) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Intensity Therapeutics reports complete pathological response in 5 of 7 patients receiving INT230-6 plus standard care in breast cancer trial

You may also like

Crypto prices